Point72 Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $67.7M | Buy |
1,199,206
+760,389
| +173% | +$44.3M | 0.09% | 272 |
|
|
2025
Q4 | $26.1M | Buy |
+438,817
| New | +$23.9M | 0.03% | 732 |
|
|
2025
Q2 | – | Sell |
-395,750
| Closed | -$28M | – | 2201 |
|
|
2025
Q1 | $28M | Buy |
395,750
+129,314
| +49% | +$8.7M | 0.06% | 357 |
|
|
2024
Q4 | $17.5M | Buy |
266,436
+68,718
| +35% | +$4.6M | 0.04% | 499 |
|
|
2024
Q3 | $13.9M | Buy |
+197,718
| New | +$16.5M | 0.04% | 535 |
|
|
2024
Q2 | – | Sell |
-1,345,720
| Closed | -$118M | – | 1886 |
|
|
2024
Q1 | $118M | Buy |
1,345,720
+890,420
| +196% | +$79.7M | 0.28% | 69 |
|
|
2023
Q4 | $43.9M | Buy |
+455,300
| New | +$40.3M | 0.11% | 248 |
|
|
2023
Q1 | – | Sell |
-716,700
| Closed | -$74.2M | – | 2243 |
|
|
2022
Q4 | $74.2M | Buy |
716,700
+121,300
| +20% | +$11.4M | 0.25% | 103 |
|
|
2022
Q3 | $50.5M | Buy |
595,400
+447,529
| +303% | +$39.8M | 0.2% | 128 |
|
|
2022
Q2 | $12.3M | Sell |
147,871
-218,965
| -60% | -$17.4M | 0.05% | 455 |
|
|
2022
Q1 | $28.3M | Sell |
366,836
-454,960
| -55% | -$38.1M | 0.11% | 240 |
|
|
2021
Q4 | $72.6M | Buy |
821,796
+30,007
| +4% | +$2.48M | 0.29% | 72 |
|
|
2021
Q3 | $61.2M | Buy |
791,789
+425,289
| +116% | +$33.6M | 0.27% | 73 |
|
|
2021
Q2 | $30.6M | Buy |
366,500
+110,000
| +43% | +$8.72M | 0.14% | 194 |
|
|
2021
Q1 | $19.4M | Sell |
256,500
-124,600
| -33% | -$10.2M | 0.09% | 273 |
|
|
2020
Q4 | $33.4M | Sell |
381,100
-562,593
| -60% | -$44.6M | 0.16% | 172 |
|
|
2020
Q3 | $71.8M | Buy |
+943,693
| New | +$95.5M | 0.37% | 54 |
|
|
2020
Q1 | – | Sell |
-260,683
| Closed | -$22M | – | 786 |
|
|
2019
Q4 | $22M | Buy |
260,683
+196,010
| +303% | +$14.8M | 0.12% | 243 |
|
|
2019
Q3 | $4.36M | Sell |
64,673
-186,973
| -74% | -$14.4M | 0.03% | 482 |
|
|
2019
Q2 | $21.6M | Buy |
+251,646
| New | +$21.5M | 0.11% | 224 |
|
|
2018
Q3 | – | Sell |
-53,703
| Closed | -$5.06M | – | 1012 |
|
|
2018
Q2 | $5.06M | Sell |
53,703
-198,397
| -79% | -$17.4M | 0.02% | 600 |
|
|
2018
Q1 | $20.4M | Sell |
252,100
-245,249
| -49% | -$21M | 0.09% | 291 |
|
|
2017
Q4 | $44.3M | Sell |
497,349
-272,193
| -35% | -$23.7M | 0.19% | 148 |
|
|
2017
Q3 | $71.6M | Buy |
+769,542
| New | +$68M | 0.32% | 77 |
|
|
2017
Q2 | – | Sell |
-364,800
| Closed | -$32M | – | 837 |
|
|
2017
Q1 | $32M | Sell |
364,800
-161,800
| -31% | -$14.4M | 0.18% | 153 |
|
|
2016
Q4 | $43.6M | Buy |
526,600
+372,900
| +243% | +$32.1M | 0.31% | 94 |
|
|
2016
Q3 | $14.2M | Buy |
+153,700
| New | +$14.5M | 0.1% | 235 |
|
|
2015
Q1 | – | Sell |
-74,600
| Closed | -$6.74M | – | 687 |
|
|
2014
Q4 | $6.74M | Sell |
74,600
-601,000
| -89% | -$50M | 0.05% | 390 |
|
|
2014
Q3 | $48.8M | Buy |
675,600
+585,500
| +650% | +$38.5M | 0.37% | 66 |
|
|
2014
Q2 | $5.61M | Buy |
+90,100
| New | +$5.44M | 0.04% | 437 |
|
Other funds holding BMRN
VCM
VPM
Point72 Asset Management's BMRN Position: Q1 2026 in Review
Point72 Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 173% in Q1 2026, buying an estimated $44.3M and bringing the position to 1,199,206 shares worth $67.7M. The position accounts for 0.09% of the portfolio, ranked #272.
Point72 Asset Management first reported a position in BMRN in Q2 2014 and has held it in 30 quarters since. The position peaked at $118M in Q1 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Point72 Asset Management held 1,199,206 shares of BioMarin Pharmaceuticals worth $67.7M as of Q1 2026.
- Point72 Asset Management bought 760,389 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $44.3M.
- BioMarin Pharmaceuticals made up 0.09% of Point72 Asset Management's portfolio in Q1 2026, its #272 holding.
- Point72 Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 30 quarters since.
- Point72 Asset Management's BioMarin Pharmaceuticals position peaked at $118M in Q1 2024.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.